

SEP 23 2004



GlaxoSmithKline

FAX

To 1614
.....
Company USPTO
.....
Fax 703-872-9306
.....
From Julie D. McFalls
.....
Tel 919-483-1545 **Fax** 919-483-7988
.....
E-mail Julie.D.McFalls@gsk.com
.....
Date September 23, 2004 **Pages including cover** 4
.....
Subject Serial No.: 10/726,752
.....
Filing Date: December 4, 2003
.....

Glaxo Wellcome Inc.
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709
Tel: 919 483 2100
www.gsk.com

Attached:

Request for Corrected Filing Receipt
USPTO Filing Receipt

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

Atty. Dkt. No. PU4727 US-1

RECEIVED
CENTRAL FAX CENTER
SEP 23 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ian Richard BUXTON et al.
Serial No.: 10/726,752
Filed: December 4, 2003
For: NOVEL FORMULATIONS AND
METHOD OF TREATMENT

Unit: 1614
Examiner:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CORRECTED FILING RECEIPT


1. Attached is a copy of the official filing receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested.

2. There is an error with respect to the following data, which is:

3. ☒ incorrectly entered and/or ☐ omitted.

- Error in
1. ☒ Applicant's name
 2. ☐ Applicant's address
 3. ☐ Title
 4. ☒ Filing date
 5. ☐ Serial Number
 6. ☐ Foreign/PCT Application Re:
 7. ☐ Other:

- Correct data
1. Gopal Muppurala
 - 2.
 - 3.
 4. 12/02/2003
 - 5.
 - 6.
 - 7.



Bonnie L. Deppenbrock
Registration No.: 28,209

Date: 23 Sept. 2004
GlaxoSmithKline
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
Phone: 919-483-1577
Fax: 919-483-7988

CERTIFICATE OF MAILING (37 CFR 1.8)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being facsimile transmitted or deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: M/S XXX, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Date: September 23, 2004


JULIE D. MCFALLS



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	PART UNIT	FILE FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/726,752	12/04/2003	1614	1590	PU4727US-1	12	44	6

CONFIRMATION NO. 6812

23347

DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY
GLAXOSMITHKLINE
FIVE MOORE DR., PO BOX 13398
RESEARCH TRIANGLE PARK, NC 27709-3398

UPDATED FILING RECEIPT

OC000000013014539

Date Mailed: 06/21/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

OK
Ian Richard Buxton (Halton Hills, CANADA;
Robin Currie, Durham, NC;
OK
Myrna A. Dela-Cruz (Brampton, CANADA;
Gary Wayne Goodson, Durham, NC;
Wlodzimierz Karolak, Mississauga, CANADA;
Mehran Maleki, North York, CANADA;
Vijay Mohan Iyer, Mississauga, CANADA;
Mupprala Gopal, Durham, NC; check name
Alan Frank Parr, Durham, NC;
Jagdey Singh Sidhu, Harlow, UNITED KINGDOM;
Robert Allen Stagner, Durham, NC;
Akunuri Venkata Vijay-Kumar, Brampton, CANADA;


Domestic Priority data as claimed by applicant

This application is a CIP of 10/629,177 07/29/2003

Foreign Applications

UNITED KINGDOM 0217493.6 07/29/2002
UNITED KINGDOM 0217492.8 07/29/2002
UNITED KINGDOM 0313801.3 06/13/2003

If Required, Foreign Filing License Granted: 01/15/2004



Projected Publication Date: 09/30/2004

Non-Publication Request: No

Early Publication Request: No

Title

Novel formulations and method of treatment

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).